Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

XenoPort Halts Mid-Stage Study of Heartburn Drug

By Pharmaceutical Processing | March 22, 2011

SANTA CLARA,
Calif. (AP) — XenoPort Inc. will
stop studying the drug candidate arbaclofen placarbil as a potential treatment
for severe heartburn symptoms after it failed to show superiority to a placebo
in a mid-stage clinical trial.

The Santa Clara,
Calif., company said the drug,
known as AP, was studied in patients with gastroesophageal reflux disease who
did not experience complete relief of symptoms while being treated with proton
pump inhibitors. Patients suffering from the condition experience acid backing
up into the esophagus, often causing burning pain in the chest.

XenoPort studied four AP dose regimens, and none showed
statistically significant improvements over a placebo. The company said it will
continue to analyze the data, but it does not believe the results warrant
further development of AP in treating the disease.

Company shares sank 11 percent, or 74 cents, to $5.93 in
morning trading.

XenoPort said it will continue planning a late-stage study
of AP in multiple sclerosis patients with spasticity. A company spokesman said
that study is expected to start by the middle of the year.

Spasticity is a condition connected to some neurological
disorders and injury to the spinal cord. It can cause decreased range of
motion, weakness, and coordination problems.

 

Related Articles Read More >

Astellas
Astellas to spend $70M on new biotech campus in South San Francisco
Rainin
Mettler Toledo Rainin expands facilities in Vacaville, California
Elemental Machines
Elemental Machines aims to enlist lab freezers in fight against climate change 
Pfizer logo
Pfizer seeks to comply with voluntary Net-Zero Standard by 2040

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards